ebomi
Colour theme
Sign in
Insider · CIK 0001257242

Durus Life Sciences Master Fund Ltd

CIK 0001257242 Name as filed on the most recent filing

Filed as Durus Life Sciences Master Fund Ltd (82)

2,121 transaction lines · from 82 filings · filed 2003-10-30 to 2004-11-19 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-28 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

2,121 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-28 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2003-03-19 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 218,454, acquired Open Form 4 filing 0000902664-03-001564
2003-03-18 P, Open-market purchase Novoste Corp /FL/NOVT 29,203, acquired Open Form 4 filing 0000902664-03-001576
2003-03-18 P, Open-market purchase Allos Therapeutics IncALTH 81,936, acquired Open Form 4 filing 0000902664-03-001557
2003-03-18 P, Open-market purchase Aksys LtdAKSY 125,488, acquired Open Form 4 filing 0000902664-03-001603
2003-03-18 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 281,678, acquired Open Form 4 filing 0000902664-03-001564
2003-03-17 P, Open-market purchase Novoste Corp /FL/NOVT 93,444, acquired Open Form 4 filing 0000902664-03-001576
2003-03-17 P, Open-market purchase Allos Therapeutics IncALTH 44,669, acquired Open Form 4 filing 0000902664-03-001557
2003-03-17 P, Open-market purchase Aksys LtdAKSY 299,663, acquired Open Form 4 filing 0000902664-03-001603
2003-03-17 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 82,538, acquired Open Form 4 filing 0000902664-03-001564
2003-03-14 S, Open-market sale Novoste Corp /FL/NOVT 2,378, disposed Open Form 4 filing 0000902664-03-001576
2003-03-14 P, Open-market purchase Novoste Corp /FL/NOVT 69,353, acquired Open Form 4 filing 0000902664-03-001576
2003-03-14 P, Open-market purchase Allos Therapeutics IncALTH 42,894, acquired Open Form 4 filing 0000902664-03-001557
2003-03-14 P, Open-market purchase Aksys LtdAKSY 2 lines 260,767, acquired Open Form 4 filing 0000902664-03-001603
2003-03-14 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 154,740, acquired Open Form 4 filing 0000902664-03-001564
2003-03-13 S, Open-market sale Novoste Corp /FL/NOVT 795, disposed Open Form 4 filing 0000902664-03-001576
2003-03-13 P, Open-market purchase Novoste Corp /FL/NOVT 311,884, acquired Open Form 4 filing 0000902664-03-001576
2003-03-13 P, Open-market purchase Aksys LtdAKSY 3 lines 660,951, acquired Open Form 4 filing 0000902664-03-001603
2003-03-13 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 837,874, acquired Open Form 4 filing 0000902664-03-001564
2003-03-13 P, Open-market purchase Allos Therapeutics IncALTH 338,561, acquired Open Form 4 filing 0000902664-03-001556
2003-03-12 P, Open-market purchase Novoste Corp /FL/NOVT 31,137, acquired Open Form 4 filing 0000902664-03-001576
2003-03-12 P, Open-market purchase Aksys LtdAKSY 2 lines 501,364, acquired Open Form 4 filing 0000902664-03-001603
2003-03-12 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 266,761, acquired Open Form 4 filing 0000902664-03-001564
2003-03-12 P, Open-market purchase Allos Therapeutics IncALTH 74,568, acquired Open Form 4 filing 0000902664-03-001556
2003-03-11 S, Open-market sale Novoste Corp /FL/NOVT 3,104, disposed Open Form 4 filing 0000902664-03-001576
2003-03-11 P, Open-market purchase Novoste Corp /FL/NOVT 1,547, acquired Open Form 4 filing 0000902664-03-001576
2003-03-11 P, Open-market purchase Aksys LtdAKSY 3 lines 692,884, acquired Open Form 4 filing 0000902664-03-001603
2003-03-11 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 523,404, acquired Open Form 4 filing 0000902664-03-001564
2003-03-11 P, Open-market purchase Allos Therapeutics IncALTH 4 lines 158,437, acquired Open Form 4 filing 0000902664-03-001556
2003-03-10 S, Open-market sale Novoste Corp /FL/NOVT 6,110, disposed Open Form 4 filing 0000902664-03-001576
2003-03-10 S, Open-market sale Aksys LtdAKSY 131,200, disposed Open Form 4 filing 0000902664-03-001603
2003-03-10 P, Open-market purchase Aksys LtdAKSY 2 lines 570,651, acquired Open Form 4 filing 0000902664-03-001603
2003-03-10 P, Open-market purchase Esperion Therapeutics Inc/MIESPR 865,923, acquired Open Form 4 filing 0000902664-03-001564
2003-03-10 P, Open-market purchase Allos Therapeutics IncALTH 6 lines 200,807, acquired Open Form 4 filing 0000902664-03-001556
2003-03-07 S, Open-market sale Novoste Corp /FL/NOVT 8,404, disposed Open Form 4 filing 0000902664-03-001576
2003-03-07 P, Open-market purchase Novoste Corp /FL/NOVT 7,760, acquired Open Form 4 filing 0000902664-03-001576

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
%, Ten percent owner
Ten percent owner

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 1,746
  • Open-market sale 375
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. DURUS LIFE SCIENCES MASTER FUND LTD, insider transactions. Retrieved 2026-08-28 from https://ebomi.com/insider/0001257242

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.